Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) dropped 0.7% during mid-day trading on Tuesday . The stock traded as low as $1.41 and last traded at $1.45. Approximately 527,206 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 1,098,452 shares. The stock had previously closed at $1.46.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on AUTL shares. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 9th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Finally, Mizuho cut their price target on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $8.75.
Get Our Latest Research Report on Autolus Therapeutics
Autolus Therapeutics Stock Down 0.7%
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The firm had revenue of $26.22 million for the quarter, compared to analyst estimates of $26.27 million. Analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.95 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after purchasing an additional 8,309 shares in the last quarter. Independent Advisor Alliance acquired a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $28,000. Marex Group plc acquired a new position in shares of Autolus Therapeutics in the 2nd quarter worth approximately $28,000. Waverly Advisors LLC bought a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $37,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of Autolus Therapeutics during the 4th quarter worth approximately $43,000. Institutional investors own 72.83% of the company’s stock.
Autolus Therapeutics Company Profile
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Featured Stories
- Five stocks we like better than Autolus Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
